Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Betuvax-CoV-2 Vaccine in Healthy Adults
NCT05270954Phase 2Unknown
- Sponsor
- Artgen Biotech
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Betuvax-CoV-2 in coronavirus disease 2019 (COVID-19), sponsored by Artgen Biotech. Status: unknown.
02
Drugs
Betuvax-CoV-2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05270954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05270954.